Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.55 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23999677 | 1.00 | KDR (0.55) | KDRMAPKAPK2EGFRMETMEN1 | |
| SCHEMBL30180457 | 0.90 | KDR (0.56) | KDRMAPKAPK2MET | |
| SCHEMBL23999898 | 0.90 | KDR (0.56) | KDRMAPKAPK2MET | |
| SCHEMBL31125054 | 0.87 | KDR (0.68) | KDRMET | |
| SCHEMBL30180450 | 0.87 | KDR (0.53) | KDRMAPKAPK2MET | |
| SCHEMBL23999675 | 0.87 | KDR (0.53) | KDRMAPKAPK2MET | |
| SCHEMBL26325453 | 0.87 | KDR (0.62) | KDRMAPKAPK2MET | |
| SCHEMBL23999547 | 0.87 | ALDH1A1 (0.47) | KDRMETMEN1KMT2ARXFP1 | |
| SCHEMBL30180498 | 0.85 | KDR (0.52) | KDRMAPKAPK2MEN1KMT2A | |
| SCHEMBL23999926 | 0.85 | KDR (0.52) | KDRMAPKAPK2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250002511-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2025-01-02 | — | — | US | disclosed |
| EP-4426279-A1 | AKT3 MODULATORS | Georgiamune Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| US-20230295114-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-09-21 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
| WO-2023081854-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2023-05-11 | — | — | WO | disclosed |
| EP-4146667-A1 | AKT3 MODULATORS | Georgiamune LLC (US) | 2023-03-15 | — | — | EP | disclosed |
| EP-4146666-A1 | AKT3 MODULATORS | Georgiamune LLC (US) | 2023-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | KDR 3433/4885MAPKAPK2 151/4885EGFR 1297/4885 |
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | KDR 3271/4885MAPKAPK2 138/4885EGFR 1128/4885 |
| US-20250002511-A1 | AKT3 MODULATORS | AKT3, PIK3C2A, PIK3C2B | KDR 1529/4885MAPKAPK2 332/4885EGFR 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.